Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri.
The Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Laryngoscope. 2019 Dec;129(12):2713-2715. doi: 10.1002/lary.27854. Epub 2019 Feb 15.
Although early glottic carcinoma is managed with radiation therapy (RT) or surgery, there is limited data on differences in second primary cancers of the larynx. We utilized the Surveillance, Epidemiology, and End Results (SEER) database to query T1 glottic carcinomas and assess the incidence of second primary laryngeal malignancies. Cumulative hazard for second primary laryngeal malignancies was compared with the log-rank method. Among 844 surgical and 2,272 RT cases, observed-to-expected incidence ratios of laryngeal second primaries were 10.19 (5.89-16.55) and 6.87 (4.64-9.81) per 10 thousand person-years, respectively. Mean person-years at risk were comparable at 8.16 years (surgery) and 8.01 years (RT), and relative increased risk of laryngeal second primary was 20.95 (surgery) versus 14.09 (RT) per 10 thousand person-years. Mean times to development of a second primary were also comparable (304 vs. 305 months, P = 0.898). Thus, second laryngeal primary development is analogous between cases treated with surgery alone versus RT. Continued discussion and investigation of surgery versus RT for early glottic squamous cell carcinoma will need to leverage these findings, along with ongoing investigation of voice and survival outcomes, to develop more well-informed treatment algorithms. Laryngoscope, 129:2713-2715, 2019.
虽然早期声门型喉癌可以通过放射治疗 (RT) 或手术治疗,但关于喉第二原发癌的差异数据有限。我们利用监测、流行病学和最终结果 (SEER) 数据库来查询 T1 声门型癌,并评估喉第二原发恶性肿瘤的发病率。采用对数秩方法比较第二原发喉恶性肿瘤的累积危险度。在 844 例手术和 2272 例 RT 病例中,观察到的与预期的喉第二原发肿瘤的发病率比值分别为每 10000 人年 10.19(5.89-16.55)和 6.87(4.64-9.81)。风险人群的平均人年数相当,分别为 8.16 年 (手术) 和 8.01 年 (RT),喉第二原发肿瘤的相对风险增加分别为 20.95(手术) 和 14.09(RT)每 10000 人年。第二原发肿瘤的发展平均时间也相似 (304 与 305 个月,P = 0.898)。因此,单独手术治疗与 RT 治疗的病例之间第二喉原发肿瘤的发展相似。对于早期声门型鳞状细胞癌的手术与 RT 治疗的进一步讨论和研究需要利用这些发现,以及对嗓音和生存结果的持续研究,制定出更明智的治疗方案。《喉镜》,129:2713-2715,2019。